Viz.ai vs VUNO

Viz.ai sells to health systems that coordinate stroke and vascular care across hospitals. VUNO sells to radiology departments that want chest X-ray triage or brain MR volumetry. The vendor says the Viz.ai platform alerts care teams through a mobile app and group messaging. ContaCT was granted De Novo DEN170073 on February 13, 2018 for large-vessel occlusion on CTA. Viz.ai's July 2026 release says 13 FDA clearances, while openFDA and De Novo list 12 records, 10 510(k)s and 2 De Novos. A 2025 Translational Stroke Research meta-analysis of 12 studies and 15,595 patients found shorter door-to-groin (SMD -0.47) and door-in-door-out (SMD -0.49) times, with no significant difference in clinical outcomes. VUNO's two openFDA decisions are K241439 (November 15, 2024, product code QFM, pleural effusion and/or pneumothorax triage) and K231398 (October 4, 2023, QIH, brain MR volumetry). Its chest page describes support for five major findings, wider than the FDA decision. A stroke network and a chest X-ray reading room are different buyers.